ABXL
ABXLKey Statistics
About ABXL
Abraxas BioScience (ABXL) is a leading biopharmaceutical innovator dedicated to developing advanced therapies for severe medical conditions characterized by significant unmet needs. Leveraging state-of-the-art technologies in drug discovery, the company is focused on a robust pipeline of proprietary drug candidates aimed at transforming patient care and improving outcomes. Committed to scientific rigor and regulatory compliance, ABXL actively collaborates with premier academic institutions and industry partners, positioning itself to expedite the development and delivery of impactful healthcare solutions to the market.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | — |
| Operating Margin | 0.00% |
| Return on Equity | 0.00% |
| Return on Assets | 0.00% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | — |
| Price-to-Book | — |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | — |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | 0 |
| Float | 0 |
| % Insiders | 0.00% |
| % Institutions | 0.00% |
Historical Volatility
Volatility is currently expanding
Turn research into an automated options-selling system
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on ABXL and any ticker you trade — then tracks every position and per-strategy win rate.